INARI AMERTRON |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.17 MYR | +0.96% |
|
+2.59% | +5.32% |
| Apr. 12 | Penumbra, Inc. : The underdog in healthcare |  |
| Feb. 26 | Inari Amertron Berhad Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
Evolution of the average Target Price on Inari Amertron
Price target over the last 5 years
History of analyst recommendation changes
b02bf4f78686f4dfaf257f7d9c59.24D2bYXkt4wS22JZvk7vf3GRzuBPjblMrSiKLeqNDCY.veXAIc-2g-RijAoL6xaKJyOo95Z24f0T4HnoeLX0emzptbg1_67u-kSQMw~1998901f17927622d1609bef312e16be
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.17
MYR
Average target price
3.409
MYR
Spread / Average Target
+7.55%
High Price Target
4.05
MYR
Spread / Highest target
+27.76%
Low Price Target
2.7
MYR
Spread / Lowest Target
-14.83%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Inari Amertron
| UBS |
Trading Rating
Investor Rating
ESG Refinitiv
B+
EPS Revisions
- Stock Market
- Equities
- INARI Stock
- Consensus Inari Amertron
